{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:45:23Z","timestamp":1782740723357,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"DOI":"10.7759\/cureus.111721","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:56:17Z","timestamp":1782737777000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Oncological Implications of Hormone Replacement Therapy in Women With Hypogonadotropic Hypogonadism: A Propensity-Matched Study"],"prefix":"10.7759","author":[{"given":"Sarah","family":"Eidbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitan","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00116","article-title":"Clinical management of congenital hypogonadotropic hypogonadism","volume":"40","author":"Young J","year":"2019","unstructured":"Young J, Xu C, Papadakis GE, et al.. Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev. 2019, 40:669-710. 10.1210\/er.2018-00116","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1184530","article-title":"New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism","volume":"14","author":"Spaziani M","year":"2023","unstructured":"Spaziani M, Carlomagno F, Tarantino C, Angelini F, Vincenzi L, Gianfrilli D. New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism. Front Endocrinol (Lausanne). 2023, 14:1184530. 10.3389\/fendo.2023.1184530","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604892","article-title":"Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy","volume":"100","author":"Kiserud CE","year":"2009","unstructured":"Kiserud CE, Foss\u00e5 A, Bj\u00f8ro T, Holte H, Cvancarova M, Foss\u00e5 SD. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009, 100:455-63. 10.1038\/sj.bjc.6604892","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae024","article-title":"Anticancer drugs-related hypogonadism in male patients with advanced cancers on active treatment: a systematic review","volume":"29","author":"Massa G","year":"2024","unstructured":"Massa G, Zambelli L, Zecca E, Shkodra M, Tin\u00e8 G, Caraceni A. Anticancer drugs-related hypogonadism in male patients with advanced cancers on active treatment: a systematic review. Oncologist. 2024, 29:e728-40. 10.1093\/oncolo\/oyae024","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000583","article-title":"Hypogonadism and cancer survivorship","volume":"27","author":"Faw CA","year":"2020","unstructured":"Faw CA, Brannigan RE. Hypogonadism and cancer survivorship. Curr Opin Endocrinol Diabetes Obes. 2020, 27:411-8. 10.1097\/MED.0000000000000583","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-023-00820-3","article-title":"Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study","volume":"36","author":"Asanad K","year":"2024","unstructured":"Asanad K, Horns JJ, Driggs N, Samplaski MK, Hotaling JM. Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study. Int J Impot Res. 2024, 36:655-8. 10.1038\/s41443-023-00820-3","journal-title":"Int J Impot Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf376","article-title":"Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study","volume":"118","author":"Wu Z","year":"2026","unstructured":"Wu Z, Wojt A, Trabert B, et al.. Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study. J Natl Cancer Inst. 2026, 118:909-16. 10.1093\/jnci\/djaf376","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02405-y","article-title":"Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer","volume":"28","author":"Nakamura M","year":"2023","unstructured":"Nakamura M, Ohba T, Sasaki R, et al.. Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer. Int J Clin Oncol. 2023, 28:1563-72. 10.1007\/s10147-023-02405-y","journal-title":"Int J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20224","article-title":"Estrogens and the risk of breast cancer: a narrative review of literature","volume":"9","author":"Al-Shami K","year":"2023","unstructured":"Al-Shami K, Awadi S, Khamees A, et al.. Estrogens and the risk of breast cancer: a narrative review of literature. Heliyon. 2023, 9:e20224. 10.1016\/j.heliyon.2023.e20224","journal-title":"Heliyon"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.05.008","article-title":"Estrogen and thrombosis: a bench to bedside review","volume":"192","author":"Abou-Ismail MY","year":"2020","unstructured":"Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020, 192:40-51. 10.1016\/j.thromres.2020.05.008","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-78818-0_10","article-title":"Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies","author":"Eliassen AH","year":"2008","unstructured":"Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Advances in Experimental Medicine and Biology. Berstein LM (ed): Springer, New York, NY; 2008. 630:148-65. 10.1007\/978-0-387-78818-0_10"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/bcr67","article-title":"Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists","volume":"2","author":"Spicer DV","year":"2000","unstructured":"Spicer DV, Pike MC. Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists. Breast Cancer Res. 2000, 2:264-7. 10.1186\/bcr67","journal-title":"Breast Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoaf017","article-title":"Premature ovarian insufficiency and the risk of breast cancer","volume":"2025","author":"Coelingh Bennink HJ","year":"2025","unstructured":"Coelingh Bennink HJ, Egberts JF, Stanczyk FZ. Premature ovarian insufficiency and the risk of breast cancer. Hum Reprod Open. 2025, 2025:hoaf017. 10.1093\/hropen\/hoaf017","journal-title":"Hum Reprod Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00685","article-title":"Estrogen replacement in young hypogonadal women \u2014 transferrable lessons from the literature related to the care of young women with premature ovarian failure and transgender women","volume":"10","author":"Swee DS","year":"2019","unstructured":"Swee DS, Javaid U, Quinton R. Estrogen replacement in young hypogonadal women \u2014 transferrable lessons from the literature related to the care of young women with premature ovarian failure and transgender women. Front Endocrinol (Lausanne). 2019, 10:685. 10.3389\/fendo.2019.00685","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-0760(00)00113-8","article-title":"Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings","volume":"74","author":"Persson I","year":"2000","unstructured":"Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol. 2000, 74:357-64. 10.1016\/s0960-0760(00)00113-8","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","volume":"370","year":"2007","unstructured":"Cervical cancer and hormonal contraceptives. collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007, 370:1609-21. 10.1016\/S0140-6736(07)61684-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33585","article-title":"Contemporary hormonal contraception and cervical cancer in women of reproductive age","author":"Iversen L","year":"2021","unstructured":"Iversen L, Fielding S, Lidegaard \u00d8, Hannaford PC. Contemporary hormonal contraception and cervical cancer in women of reproductive age. Int J Cancer. 2021, 10.1002\/ijc.33585","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147029","article-title":"The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort","volume":"11","author":"Roura E","year":"2016","unstructured":"Roura E, Travier N, Waterboer T, et al.. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. 2016, 11:e0147029. 10.1371\/journal.pone.0147029","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-026-01535-y","article-title":"Management of infertility in women with hypothalamic hypogonadotropic hypogonadism: an expert opinion","volume":"24","author":"Robin G","year":"2026","unstructured":"Robin G, Maitrot-Mantelet L, Dubourdieu S, Kiehl-Bigot B, Katsogiannou M, De Vos M, Christin-Maitre S. Management of infertility in women with hypothalamic hypogonadotropic hypogonadism: an expert opinion. Reprod Biol Endocrinol. 2026, 24:10.1186\/s12958-026-01535-y","journal-title":"Reprod Biol Endocrinol"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1995.03530240036037","article-title":"Serum gonadotropins and steroid hormones and the development of ovarian cancer","volume":"274","author":"Helzlsouer KJ","year":"1995","unstructured":"Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995, 274:1926-30.","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.98.14.1","article-title":"Endogenous hormones and ovarian cancer: epidemiology and current hypotheses","volume":"14","author":"Lukanova A","year":"2005","unstructured":"Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005, 14:98-107.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv210","article-title":"A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women","volume":"107","author":"Murphy N","year":"2015","unstructured":"Murphy N, Strickler HD, Stanczyk FZ, et al.. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst. 2015, 107:10.1093\/jnci\/djv210","journal-title":"J Natl Cancer Inst"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2946","article-title":"Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women","volume":"68","author":"Gunter MJ","year":"2008","unstructured":"Gunter MJ, Hoover DR, Yu H, et al.. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008, 68:329-37. 10.1158\/0008-5472.CAN-07-2946","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.2248","article-title":"Endometrial cancer: a review","volume":"335","author":"Mager KL","year":"2026","unstructured":"Mager KL, McLean K. Endometrial cancer: a review. JAMA. 2026, 335:1616-27. 10.1001\/jama.2026.2248","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.129411","article-title":"Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women","volume":"56","author":"Freedman ND","year":"2007","unstructured":"Freedman ND, Chow WH, Gao YT, et al.. Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. Gut. 2007, 56:1671-7. 10.1136\/gut.2007.129411","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-023-01829-1","article-title":"Reproductive factors, hormonal interventions, and gastric cancer risk in the Stomach cancer Pooling (StoP) Project","volume":"35","author":"Song M","year":"2024","unstructured":"Song M, Jayasekara H, Pelucchi C, et al.. Reproductive factors, hormonal interventions, and gastric cancer risk in the Stomach cancer Pooling (StoP) Project. Cancer Causes Control. 2024, 35:727-37. 10.1007\/s10552-023-01829-1","journal-title":"Cancer Causes Control"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico M","year":"2008","unstructured":"Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008, 336:1227-31. 10.1136\/bmj.39555.441944.BE","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202438","article-title":"Sex hormone influences on venous thrombotic and cardiovascular risk","volume":"394","author":"Skeith L","year":"2026","unstructured":"Skeith L, Bates SM. Sex hormone influences on venous thrombotic and cardiovascular risk. N Engl J Med. 2026, 394:1514-28. 10.1056\/NEJMra2202438","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova Y","year":"2019","unstructured":"Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019, 364:k4810. 10.1136\/bmj.k4810","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00342-8","article-title":"Hypopituitarism","volume":"403","author":"Fleseriu M","year":"2024","unstructured":"Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Hypopituitarism. Lancet. 2024, 403:2632-48. 10.1016\/S0140-6736(24)00342-8","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498351-long-term-oncological-implications-of-hormone-replacement-therapy-in-women-with-hypogonadotropic-hypogonadism-a-propensity-matched-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:56:19Z","timestamp":1782737779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498351-long-term-oncological-implications-of-hormone-replacement-therapy-in-women-with-hypogonadotropic-hypogonadism-a-propensity-matched-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111721","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}